US Pharmaceutical Leaders in FY2025 Reveal New Manufacturing and Investment Opportunities
US pharmaceutical industry brings together some of the world's largest drug manufacturers and biotechnology companies. Their FY2025 revenues reveal not only their financial scale but also the competitive strength of their portfolios and commercial operations.
Top 10 US-Headquartered Companies by FY2025 Revenue
| Rank | Company | FY2025 Revenue |
|---|---|---|
| 1 | Johnson & Johnson | $94.19B |
| 2 | Eli Lilly | $65.18B |
| 3 | Merck & Co. | $65.01B |
| 4 | Pfizer | $62.58B |
| 5 | AbbVie | $61.16B |
| 6 | Bristol Myers Squibb | $48.19B |
| 7 | Abbott Laboratories | $44.33B |
| 8 | Amgen | $36.75B |
| 9 | Gilead Sciences | $29.44B |
| 10 | Regeneron Pharmaceuticals | $14.34B |
What Do the FY2025 Results Reveal?
1. Johnson & Johnson Maintains the Largest Revenue Base
Johnson & Johnson reported $94.19 billion in worldwide sales for FY2025, retaining the leading position in this group.
Its business is supported by two major segments: Innovative Medicine, which generated $60.40 billion, and MedTech, which generated $33.79 billion.
This diversified structure creates opportunities across pharmaceutical manufacturing, medical technologies, surgical products and healthcare supply chains.
2. Eli Lilly Records Strong Revenue Growth
Eli Lilly generated $65.18 billion in FY2025 revenue, representing approximately 45% growth compared with 2024.
Mounjaro and Zepbound were major contributors. Combined revenue from these two products was approximately $36.51 billion, highlighting the commercial importance of its incretin-based portfolio.
This performance has implications for API suppliers, injectable drug manufacturers, packaging companies and CDMOs supporting complex pharmaceutical production.
3. Merck, Pfizer and AbbVie Maintain Significant Industry Scale
Merck & Co., Pfizer and AbbVie each reported more than $60 billion in annual revenue.
Their portfolios span oncology, immunology, vaccines, specialty medicines and other therapeutic areas. Their scale creates opportunities for manufacturing partnerships, formulation development, supply-chain services and external innovation.
However, revenue alone does not indicate future growth. Patent expirations, product concentration, pipeline performance and competition from biosimilars and generics also influence long-term business prospects.
4. Biopharmaceutical Specialists Remain Important
Amgen, Gilead Sciences and Regeneron represent important players in biologics, oncology, immunology, cell therapy and other specialised treatment areas.
Their development and commercial activities create demand for specialised manufacturing, biologics process development, analytical testing, cold-chain logistics and technology partnerships.
Where Are the Business Opportunities?
Pharmaceutical and Biopharmaceutical Manufacturing
Large pharmaceutical portfolios require reliable production capacity across APIs, intermediates, formulations and finished-dose products.
Manufacturers can assess opportunities in sterile injectables, oral solid dosage, biologics and specialised formulations based on the requirements of individual companies.
CDMO Partnerships and Outsourcing
Pharmaceutical companies use contract development and manufacturing organisations to access specialised technologies, additional production capacity and development expertise.
Potential opportunities include:
-
Sterile and injectable manufacturing.
-
Biologics and monoclonal antibody production.
-
Analytical development and quality testing.
-
Commercial-scale manufacturing.
-
Packaging and supply-chain services.
Biologics, ADCs and Cell and Gene Therapies
Growing investment in complex therapies creates demand for specialised manufacturing capabilities.
Opportunities include antibody-drug conjugate production, cell and gene therapy manufacturing, viral vector development, biologics testing and advanced formulation technologies.
Companies with validated facilities, regulatory experience and scalable production capabilities may be better positioned to secure partnerships.
Patent Expirations and Biosimilar Competition
Patent expirations can create opportunities for generic drug manufacturers and biosimilar developers.
However, companies must evaluate patent protection, regulatory pathways, manufacturing complexity, pricing pressure and market access before entering a product category.
Licensing, M&A and Pipeline Investments
Pharmaceutical leaders continue to assess external innovation to strengthen their product portfolios and access new technologies.
Biotechnology companies with differentiated clinical assets, specialised platforms or manufacturing capabilities can explore licensing, co-development and acquisition opportunities.
What Should Manufacturers and Investors Evaluate?
Revenue rankings provide an initial view of company scale, but they are not sufficient for identifying commercial opportunities.
Before approaching a pharmaceutical company or investing in a segment, decision-makers should evaluate:
-
Product portfolio: Therapeutic areas, leading products and pipeline priorities.
-
Manufacturing requirements: In-house capacity, outsourced production and technology needs.
-
Competitive positioning: Key competitors, patent exposure and biosimilar activity.
-
Partnership activity: Licensing agreements, acquisitions and CDMO relationships.
-
Regional presence: Manufacturing facilities, supply networks and target markets.
-
Growth potential: Clinical pipeline progress, product launches and investment priorities.
This analysis helps manufacturers identify relevant buyers, suppliers and partnership opportunities instead of relying only on company revenue.
How Towards Healthcare Supports Strategic Decisions
Towards Healthcare Research & Consulting provides industry intelligence to help pharmaceutical companies, manufacturers, CDMOs and investors evaluate competitive positions and commercial opportunities.
Our capabilities include:
-
Complete Master Datasets: Company profiles, product portfolios and industry intelligence.
-
Competitive Quadrants: Assessment of leading companies and their competitive positions.
-
Pipeline Intelligence: Tracking of clinical developments, drug candidates and regulatory milestones.
-
CDMO Research: Assessment of manufacturing capabilities, facilities and outsourcing opportunities.
-
Buyer Identification: Identification of relevant pharmaceutical companies and decision-makers.
-
Customized Dashboards: Structured intelligence to support business planning and strategic decisions.
About Us
Healthcare WebWire is a part of Towards Healthcare, which is a healthcare intelligence and market research company specializing in market intelligence, competitive intelligence, customer intelligence, pipeline intelligence, market sizing and commercial strategy across pharmaceutical, biotechnology, medical device and healthcare markets.
Contact us for quick meeting, customized data, free samples or further enquiry at [email protected]
Europe Region - +44 778 256 0738
North America Region - +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com